GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (STU:RB0) » Definitions » Notes Receivable

Regenxbio (STU:RB0) Notes Receivable : €0.0 Mil (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Regenxbio Notes Receivable?

Regenxbio's Notes Receivable for the quarter that ended in Mar. 2025 was €0.0 Mil.


Regenxbio Notes Receivable Historical Data

The historical data trend for Regenxbio's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenxbio Notes Receivable Chart

Regenxbio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regenxbio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Regenxbio Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Regenxbio Notes Receivable Related Terms

Thank you for viewing the detailed overview of Regenxbio's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenxbio Business Description

Traded in Other Exchanges
Address
9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Regenxbio Headlines

No Headlines